Teva Pharmaceutical Industries Ltd Archives

Home / Posts tagged Teva Pharmaceutical Industries Ltd

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC. Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, [...]

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Actor and comedian, Will Forte, opens up about his brother-in-law’s journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1 Teva’s Honestly HD program provides educational information about [...]

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2 Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in pediatric [...]

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease Funding agreement supports Teva’s Pivot to Growth [...]

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Jan. 05, 2026 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access [...]

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody’s affirmed Teva’s B1a rating and revised Teva’s outlook to positive from stable S&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. [...]

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (Korea Bizwire) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development [...]

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-’749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this [...]

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva’s first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth Strategy Rise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact [...]